Back to results
US 2021/0330740 A1Published application
Runx3 modified protein for prevention or treatment of cancer
AssigneeRun-x Corporation
InventorsSuk Chul Bae, Jung Won Lee, You Soub Lee
Life of this patent
Estimating the term…
Loading patent…
Loading patent…
AssigneeRun-x Corporation
InventorsSuk Chul Bae, Jung Won Lee, You Soub Lee
Estimating the term…
In the present invention, it was confirmed that the modified protein in which the 356th serine of Runx3 is substituted with alanine has an increased activity of maintaining the complex with Brd2 by more than 10 times compared to the wild-type Runx3, and the apoptosis effect is improved in various cancer cell lines compared to the wild-type Runx3. Therefore, the modified protein in which the 356th serine of Runx3 is substituted with an amino acid that cannot be phosphorylated by a kinase of the present invention, the polynucleotide coding thereof, the vector carrying the polynucleotide, or the virus or cell transformed with the vector can be used as a therapeutic agent for various cancers.
A method for treating cancer comprising a modified protein in which the 356th serine of Runx3 (Runt-related transcription factor 3) protein is substituted with an amino acid that cannot be phosphorylated by a kinase, a polynucleotide encoding thereof, a vector carrying the polynucleotide, or a virus or cell transformed with the vector in a pharmaceutically effective amount to a subject in need thereof.
Dependencies are inferred from the claim text.